Background: The aim of the study was to evaluate the association of high-resolution computed tomography (HRCT) findings with pulmonary fibrotic activity in the corresponding regions using [ 68 Ga]Ga-fibroblast activation fibroblast inhibitor (FAPI) PET/CT in patients with interstitial lung disease (ILD). Additionally, the potential of [ 68 Ga]Ga-FAPI-46 PET/CT for evaluating the active fibrosis process and 99m Tc-MIBI scintigraphy for assessing the inflammatory process in ILD patients was also assessed.
Methods: In this pilot study, 20 ILD patients underwent [ 68 Ga]Ga-FAPI-46 PET/CT and 99m Tc-MIBI SPECT/CT. Additionally, 10 patients without lung or thoracic involvement who were undergoing [ 68 Ga]Ga-FAPI PET/CT for cancer detection were enrolled in the control group. The images were evaluated both visually and semiquantitatively and also compared with HRCT and pulmonary function tests. Multiple quantitative parameters were derived from the lung segments in the PET scan, including SUV max , SUV mean , maximum target-to-liver ratio, mean target-to-liver ratio (TLR mean ), and total lesion FAPI expression for the entire lung, as well as its lobes and zones. Additionally, the maximum Hounsfield unit (HU) and mean HU in HRCT were calculated for the whole lung as well as its lobes and zones. Furthermore, an HRCT fibrosis score (HFS) was defined according to the HRCT findings.
Results: Twenty ILD patients with a mean age of 58.70 (SD, 11.09) years were enrolled. Additionally, 10 control patients were enrolled with a mean age of 57.70 (SD, 15.19) years. Based on visual assessment, the FAPI scan was positive in 12 (60%) patients. Similarly, the MIBI scan was positive in 12 (60%) patients. In the 20 ILD cases, both scans were positive in 6 cases, and both were negative in 2 cases. Six cases showed FAPI-negative and MIBI-positive results, whereas another 6 cases showed FAPI-positive and MIBI-negative results. Comparing the control and ILD patients, there was a significant difference in SUV max , SUV mean , total lesion FAPI expression, TLR mean , maximum HU, and mean HU ( P < 0.05). When comparing HFS with PET-derived parameters in zones, a significant positive correlation was found between HFS and SUV mean , SUV max , maximum target-to-liver ratio, and TLR mean ( P < 0.05). Additionally, a significant difference was noted between FAPI results and HFS ( P = 0.003). An ancillary finding, 9 of 20 (45%) ILD patients showed intense FAPI uptakes in gallbladder, whereas none of the 10 in the control group showed such uptake.
Conclusion: The present study may suggest that combining [ 68 Ga]Ga-FAPI PET/CT and 99m Tc-MIBI SPECT/CT yields an additive effect for evaluating ILD-related fibrosis and inflammatory processes over using either modality alone. Furthermore, it appears that [ 68 Ga]Ga-FAPI PET/CT has the potential to ascertain levels of fibrotic activity from population of resident fibroblasts, active fibroblasts, and scar maturation among ILD patients based on their HRCT patterns.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/RLU.0000000000005505 | DOI Listing |
Med Biol Eng Comput
January 2025
Department of Biomedical Engineering, Indian Institute of Technology, Ropar, Punjab, India.
Blood pressure (BP) is one of the vital physiological parameters, and its measurement is done routinely for almost all patients who visit hospitals. Cuffless BP measurement has been of great research interest over the last few years. In this paper, we aim to establish a method for cuffless measurement of BP using ultrasound.
View Article and Find Full Text PDFFront Cell Infect Microbiol
December 2024
Center for Metabolic and Degenerative Diseases, The Brown Foundation Institute of Molecular Medicine for Prevention of Human Diseases, UTHealth-McGovern Medical School, Houston, TX, United States.
Interstitial lung disease (ILD) is characterized by chronic inflammation and scarring of the lungs, of which idiopathic pulmonary fibrosis (IPF) is the most devastating pathologic form. Idiopathic pulmonary fibrosis pathogenesis leads to loss of lung function and eventual death in 50% of patients, making it the leading cause of ILD-associated mortality worldwide. Persistent and subclinical microbial infections are implicated in the acute exacerbation of chronic lung diseases.
View Article and Find Full Text PDFRespir Med
January 2025
CIR Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom. Electronic address:
Background: Interstitial Lung Disease (ILD) is characterised by dyspnoea, reduced exercise capacity and poor health related quality of life (HRQoL). The evidence to support the benefits of pulmonary rehabilitation (PR) on exercise capacity (EC) and HRQoL in this population is still limited. We aimed to determine the effect of the different PR components on exercise capacity and HRQoL in patients with ILD.
View Article and Find Full Text PDFJ Thorac Oncol
January 2025
Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawa-Nishi-machi, Kanagawa-ku, Yokohama 221-0855, Japan.
Introduction: Osimertinib is the first-line treatment for patients with non-small cell lung cancer (NSCLC) who have EGFR mutations and favorable performance status (PS). Despite increasing clinical data on osimertinib, evidence in patients with an impaired PS remains limited. Therefore, a multicenter phase II trial (OPEN/TORG2040) was conducted to evaluate the efficacy and safety of first-line osimertinib for patients with EGFR mutation-positive NSCLC and poor PS.
View Article and Find Full Text PDFObjectives: We aimed to assess the anti-mutated citrullinated vimentin (anti-MCV) antibodies in RA patients' serum and to explore their association with interstitial lung disease (ILD).
Methods: Eighty rheumatoid arthritis (RA) patients and forty healthy controls were included in this case-control study. Of these patients, forty had ILD, and forty without ILD.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!